Company: GAUZ
Filing Date: 2025-03-11
Form Type: 20-F
Source: 0001213900-25-022437
Chunk: 82

Company: Gauzy Ltd.
Filing Date: 2025-03-11
Form: 20-F
Item: Item 6
Chunk 82
---
 Limited.
-------------------------------------------------------

●    Danny Allouche was appointed 
    by Avery Dennison Corporation.
----------------------------------

●           Ezriel Jesse Klein was        
    appointed by Blue-Red Capital Fund LP.
------------------------------------------

●   Lilach Payorski was appointed
            by our Board.        
---------------------------------
B. Compensation

Compensation of directors and executive officers

The aggregate compensation paid by us to our directors and executive officers, including share-based compensation expenses recorded in our consolidated financial statements for the year ended December 31, 2024, was approximately $3.92 million. This amount includes deferred or contingent compensation accrued for such year and excludes deferred or contingent amounts accrued during the year ended December 31, 2023, and paid during the year ended December 31, 2024.

We pay each of our non-employee directors an annual cash payment of $50,000 with an additional annual payment for service on board committees as follows: $10,000 (or $20,000 for the chairperson) for each member of our audit committee and $7,500 (or $15,000 for the chairperson) for each member of our compensation committee.

89

In addition, (i) our non-employee directors who served in such capacity as of the first business day in Israel following the 30th trading day of our shares on Nasdaq are eligible to receive a grant of options under our 2016 Plan with a value of $150,000, and (ii) thereafter, following each annual general meeting of our shareholders, our non-employee directors shall be granted options under our 2016 Plan (provided the director is still in office) with a value of $150,000 (with prorated awards granted to non-employee directors who join the Board on a date other than an annual general meeting of our shareholders). The options will vest over a three-year period with one-third vesting on the one-year anniversary of the date of grant and the remainder vesting in equal parts at the end of each calendar quarter thereafter, subject to acceleration upon a “Merger/Sale” (as defined in the 2016 Plan) and have an exercise price equal to the 30-trading days’ average closing price of our ordinary shares prior to the date of grant. We refer to the above as our “Non-Employee Director Equity Arrangement”.

For so long as we qualify as a foreign private issuer, we are not required to comply with the director and executive compensation disclosure requirements applicable to U.S